DB Power and LPA announce strategic partnership to globally expand solutions for issuers of structured retail products

Real Time Search
CES A80 :
CES HKMI :
CES 120 :
Total Turn.

09606 DUALITYBIO-B

Closed Add to Porfolio
Index Constituent : None
Major Shareholders Shi Yi (18.95%)
King Star Med LP (7.49%)
ZHU Zhongyuan (7.38%)
Shanghai Yingjia Enterprise Management Partnership (Limited Partnership) (7.26%)		 Sector Health Care & Biotechnology
Web Site http://www.dualitybiologics.com Tel N/A
Email N/A Fax N/A
Related Equities N/A
Principal Activities The Group is a global clinical-stage biopharmaceutical company discovering, developing next generation Antibody-Drug Conjugate therapeutics in the People’s Republic of China (the “PRC”) and United States of America (the “US”).

Consolidated List of Substantial Shareholders

Name Number of Shares Interested % of Issued Share Capital (%) Date of Last Notice Filed (Y/M/D)
Last Update :
Note : (L) - Long Position (S) - Short Position (P) - Lending Pool

Complete List of Directors

Director's Name Number of Shares Interested % of issued share capital (%) Date of Last Notice Filed (Y/M/D)
Last Update :
Note : (L) - Long Position (S) - Short Position (P) - Lending Pool
Back to Top